Literature DB >> 15059068

Intracellular IL-4/IFN-gamma producing peripheral T lymphocyte subsets in B cell non-Hodgkin's lymphoma patients.

Lajos Gergely1, Magdolna Aleksza, László Váróczy, Andrea Ponyi, Sándor Sipka, Arpád Illés, Gyula Szegedi.   

Abstract

AIM: The availability of several biological therapy options is rapidly growing in the field of malignant lymphomas. This emphasizes the need to understand the precise interaction of the host immune system with the malignant disease. We measured the intracellular cytokine responses in lymphoma patients' lymphocytes, to characterize the polarization changes in their immune system.
METHODS: Patients with B cell non-Hodgkin's lymphoma were involved in the study. Peripheral lymphocytes were labeled with anti-CD4 or anti-CD8 antibodies and intracellular accumulation of IL-4 or IFN-gamma was detected after in vitro incubation the cells with activating cocktail. The frequency of different T-cell subsets were measured within the lymphocyte population.
RESULTS: Significantly increased CD4+, IFN-gamma producing (Th1) cell percentage were found in untreated lymphoma cases (28.8% vs. 21.8%). CD8+ IL-4 and IFN-gamma producing (Tc0) T cell frequency is significantly higher in untreated lymphoma patients compared with normal controls (1.3% vs. 0.47%). The frequency of CD4+ IL-4 producing (Th2) cells is significantly lower in untreated patients (0.96% vs. 1.19%). Patients in long-term remission have lower frequency of CD4+, IL4 producing (Th2) cell ratio (0.31% vs. 1.19%) and increased CD4+ IFN-gamma producing (Th1) cell frequency (30.1% vs. 21.8%), compared with healthy normal controls.
CONCLUSION: Our results demonstrate that there is a sustained increase in the CD4+ IFN-gamma producing cell frequency in lymphoma patients. The frequency of CD4+ IL-4 producing cells is decreasing by treatment. These may contribute to strong polarization toward Th1 type response, needed for lymphoma clearance and remission. Copyright Blackwell Munksgaard 2004.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15059068     DOI: 10.1111/j.1600-0609.2004.00234.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  5 in total

1.  Cytokine polymorphisms in the Th1/Th2 pathway and susceptibility to non-Hodgkin lymphoma.

Authors:  Qing Lan; Tongzhang Zheng; Nathaniel Rothman; Yawei Zhang; Sophia S Wang; Min Shen; Sonja I Berndt; Shelia H Zahm; Theodore R Holford; Brian Leaderer; Meredith Yeager; Robert Welch; Peter Boyle; Bing Zhang; Kaiyong Zou; Yong Zhu; Stephen Chanock
Journal:  Blood       Date:  2006-01-31       Impact factor: 22.113

2.  Cytokine polymorphisms in Th1/Th2 pathway genes, body mass index, and risk of non-Hodgkin lymphoma.

Authors:  Yingtai Chen; Tongzhang Zheng; Qing Lan; Francine Foss; Christopher Kim; Xuezhong Chen; Min Dai; Yumin Li; Theodore Holford; Brian Leaderer; Peter Boyle; Stephen J Chanock; Nathaniel Rothman; Yawei Zhang
Journal:  Blood       Date:  2010-10-15       Impact factor: 22.113

3.  Vaccination history and risk of non-Hodgkin lymphoma: a population-based, case-control study.

Authors:  Heather A Lankes; Angela J Fought; Andrew M Evens; Dennis D Weisenburger; Brian C-H Chiu
Journal:  Cancer Causes Control       Date:  2008-11-15       Impact factor: 2.506

4.  Complete remission of splenic marginal zone lymphoma after an acute flare-up of hepatitis B in a hepatitis B virus carrier.

Authors:  Katsuya Fujimoto; Tomoyuki Endo; Mitsufumi Nishio; Masato Obara; Keisuke Yamaguchi; Yukari Takeda; Hideki Goto; Ikumi Kasahara; Norihiro Sato; Takao Koike
Journal:  Int J Hematol       Date:  2009-10-06       Impact factor: 2.490

5.  Polymorphisms in Th1/Th2 cytokine genes, hormone replacement therapy, and risk of non-Hodgkin lymphoma.

Authors:  Gongjian Zhu; Dongsheng Pan; Tongzhang Zheng; Qing Lan; Xuezhong Chen; Yingtai Chen; Christopher Kim; Xiaofeng Bi; Theodore Holford; Peter Boyle; Brian Leaderer; Stephen J Chanock; Nathaniel Rothman; Yawei Zhang
Journal:  Front Oncol       Date:  2011-07-28       Impact factor: 6.244

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.